SANA BIOTECHNOLOGY INC
NASDAQ: SANA (Sana Biotechnology, Inc.)
Last update: 8 hours ago5.31
-0.62 (-10.39%)
| Previous Close | 5.92 |
| Open | 6.03 |
| Volume | 14,692,080 |
| Avg. Volume (3M) | 5,377,971 |
| Market Cap | 1,364,713,728 |
| Price / Book | 8.33 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -0.880 |
| Total Debt/Equity (MRQ) | 43.67% |
| Current Ratio (MRQ) | 3.40 |
| Operating Cash Flow (TTM) | -206.18 M |
| Levered Free Cash Flow (TTM) | -118.45 M |
| Return on Assets (TTM) | -23.84% |
| Return on Equity (TTM) | -71.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Sana Biotechnology, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | 1.5 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -0.20 |
|
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.46% |
| % Held by Institutions | 89.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Flagship Pioneering Inc. | 30 Jun 2025 | 25,001,856 |
| Canada Pension Plan Investment Board | 30 Jun 2025 | 10,175,000 |
| Marex Group Plc | 30 Jun 2025 | 3,817,780 |
| Crestline Management, Lp | 30 Jun 2025 | 2,420,937 |
| Baker Bros. Advisors Lp | 30 Jun 2025 | 2,030,949 |
| Integral Health Asset Management, Llc | 30 Jun 2025 | 1,500,000 |
| 52 Weeks Range | ||
| Median | 5.00 (-5.75%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 24 Sep 2025 | 5.00 (-5.75%) | Buy | 3.41 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BISHOP HANS EDGAR | 4.16 | - | 5,628 | 23,412 |
| Aggregate Net Quantity | 5,628 | |||
| Aggregate Net Value ($) | 23,412 | |||
| Aggregate Avg. Buy ($) | 4.16 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BISHOP HANS EDGAR | Director | 06 Oct 2025 | Acquired (+) | 5,628 | 4.16 | 23,412 |
| Date | Type | Details |
|---|---|---|
| 26 Aug 2025 | Announcement | Sana Biotechnology to Present at September 2025 Investor Conferences |
| 20 Aug 2025 | Announcement | Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares |
| 11 Aug 2025 | Announcement | Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates |
| 06 Aug 2025 | Announcement | Sana Biotechnology Announces Pricing of Public Offering |
| 06 Aug 2025 | Announcement | Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants |
| 04 Aug 2025 | Announcement | Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |